Stoke presents STK-002 data. Stoke Therapeutics stock is valued at USD 1.5 billion

Published on 10/15/2026 at 13:31 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Stoke showed two STK-002 presentations at AAO on October 12, 2026. Stoke Therapeutics stock costs EUR 20.83 on October 15, 2026.

Clinical milestones and reporting date

Two STK-002 presentations were scheduled for the AAO meeting on October 12, 2026.
European enrollment added 34 patients in August 2026.
Stoke Therapeutics stock was trading at EUR 20.83 at 1:18 p.m. CEST at Lang & Schwarz on October 15, 2026.
Third-quarter results are estimated for November 3, 2026.
The market capitalization was USD 1.5 billion as of October 14, 2026.

STOK, US86150R1077, Illustration mit AI erstellt.

Stoke Therapeutics (ISIN US86150R1077) was trading at EUR 20.83 at Lang & Schwarz on October 15, 2026 at 1:18 p.m. CEST. The company presented two sets of STK-002 data at the American Academy of Ophthalmology meeting, according to Morningstar on October 12, 2026. The stock's market capitalization was USD 1.5 billion as of October 14, 2026.

FDA path sets the timetable

Stoke's October 5, 2026 FDA meeting focused on the planned U.S. New Drug Application for zorevunersen, the company's investigational treatment for Dravet syndrome. The company plans a Phase 3 EMPEROR readout in the third quarter of 2027 and an NDA submission in the second half of 2027, according to Stoke Therapeutics.

What do the trials add?

The October data centered on STK-002, an antisense oligonucleotide in the OSPREY Phase 1 study for autosomal dominant optic atrophy. Dosing of the first two cohorts was complete, while dosing of the third cohort was expected to finish by the end of 2026. Initial safety and efficacy results are anticipated in the first half of 2027.

Three milestones shape the pipeline

In June 2026, enrollment in the EMPEROR study was complete in the United States, United Kingdom and Japan. A further European cohort added 34 patients in August 2026, while enrollment continued in China, according to the FDA meeting release. On October 12, 2026, the AAO presentations supplied the latest clinical update, making the sequence relevant for investors tracking two separate development programs.

What dates come next?

Stoke is estimated to report third-quarter 2026 results on November 3, 2026, after the market closes, according to MarketBeat. The planned Phase 3 readout in the third quarter of 2027 is the next major clinical date.

Revenue growth meets cash demands

Second-quarter 2026 revenue reached USD 9.33 million, above the USD 5.19 million consensus estimate, while adjusted earnings per share were negative USD 0.93 against a negative USD 0.77 estimate, according to Investing.com. The combination leaves clinical execution and funding needs as the central measures for the next reporting cycle.

Stock trades at Lang & Schwarz

Stoke Therapeutics was trading at EUR 20.83 at Lang & Schwarz on October 15, 2026 at 1:18 p.m. CEST. The further course of trading is shown by the continuously updated real-time quote of Stoke Therapeutics stock.